



## MediWound to Report Fourth Quarter and Full Year 2023 Financial Results

March 14, 2024

### Conference Call and Webcast Scheduled for Thursday, March 21st at 8:30 am Eastern Time

YAVNE, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its financial results for the fourth quarter and full year ended December 31, 2023 on Thursday, March 21, 2024.

Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide corporate updates, and answer questions.

Dial-in and call details are as follows:

#### **Conference Call & Webcast**

##### **Details**

Toll-Free: 1-833-630-1956

Israel: 1-80-921-2373

International: 1-412-317-1837

Webcast: [Click HERE](#)

To access the call, participants should dial the **applicable** telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website.

#### **About MediWound**

MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. MediWound specializes in the development, production and commercialization of solutions that seek to improve existing standards of care. The Company is committed to providing rapid and effective biologics that improve patient experiences and outcomes, while reducing costs and unnecessary surgeries.

MediWound's first drug, NexoBrid<sup>®</sup>, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&D pipeline including the Company's lead drug under development, EscharEx<sup>®</sup>. EscharEx is a Phase III-ready biologic for debridement of chronic wounds with significant potential advantages over the \$360 million dominant product and an opportunity to expand the market. MediWound's pipeline also includes MW005, a topical therapeutic for the treatment of basal cell carcinoma that has demonstrated positive results in a Phase I/II study.

For more information visit [www.mediwound.com](http://www.mediwound.com) and follow the Company on [LinkedIn](#) and [X](#).

#### **MediWound Contacts:**

Hani Luxenburg

Chief Financial Officer

MediWound Ltd.

[ir@mediwound.com](mailto:ir@mediwound.com)

Daniel Ferry

Managing Director

LifeSci Advisors, LLC

[daniel@lifesciadvisors.com](mailto:daniel@lifesciadvisors.com)

#### **Media Contact:**

Ellie Hanson

FINN Partners for MediWound

[ellie.hanson@finnpartners.com](mailto:ellie.hanson@finnpartners.com)

929-588-2008